Thelansis

Japan has quietly turned its HTA framework into one of the most influential, but often misunderstood, pricing systems in major markets. Since formal cost-effectiveness evaluation became part of the NHI price-setting process in 2019, the country has refined its approach almost every year. The 2024-25 policy cycle marks another step in that evolution, with changes that will matter to anyone planning global launches over the next two to three years. For companies preparing for Japan, the question is no longer “ Will HTA affect our launch? ” It’s “ How early do we start shaping our value story so the HTA process doesn’t dilute our price once we’re on the market? ” What Has Actually Changed by 2025? A few updates drive most of the practical impact: 1. Cost-effectiveness evaluation is now routine in defined situations Japan continues to require manufacturers to submit health-economic analyses when list prices are high, premiums are involved, or comparator uncertainty is high. The...

For many biopharma teams, Phase III is treated as the final mountain to climb. Once efficacy and safety are proven, commercial readiness is assumed to follow naturally. In reality, that assumption is one of the most costly missteps in drug development. More assets than ever are reaching regulatory approval on time, yet facing slower-than-expected uptake, prolonged access negotiations, or restrictive reimbursement decisions. The issue isn’t clinical failure. It’s evidence of misalignment. Approval is Not the Same as Readiness Phase III trials are designed to answer a specific question: Does the therapy work, and is it safe? Regulators care deeply about this, and rightly so. But payers, HTA bodies, and health systems are solving a different problem altogether. They are deciding who should receive the therapy, when, and at what cost to the system, rather than what. When evidence is optimized only for approval, commercial teams are often left trying to retrofit value stories after ...